FIELD: biotechnology.
SUBSTANCE: present invention relates to the field of biotechnology. A method for determining the clinical efficacy of sorafenib for the treatment of kidney carcinoma in a patient is proposed.
EFFECT: invention may find further application in the treatment of renal carcinoma.
7 cl, 5 dwg, 5 tbl, 4 ex
Title | Year | Author | Number |
---|---|---|---|
METHOD FOR DETECTING TYROSINE KINASE RECEPTOR GENE TRANSLOCATIONS IN TUMOUR TISSUE SAMPLES USING RNA SEQUENCING DATA | 2023 |
|
RU2814710C1 |
METHOD FOR PREDICTION OF SURVIVAL IN PATIENTS WITH CLEAR CELL RENAL CELL CARCINOMA | 2018 |
|
RU2699792C1 |
ONCOBOX GENETIC INFORMATION ANALYSIS PLATFORM | 2018 |
|
RU2741703C1 |
METHOD OF CREATING TARGET PANEL FOR STUDYING GENOMIC REGIONS FOR DETECTING THERAPEUTIC BIOMARKERS OF IMMUNE CHECKPOINT (IC) INHIBITORS | 2023 |
|
RU2818360C1 |
FGFR EXPRESSION AND SENSITIVITY TO FGFR INHIBITOR | 2016 |
|
RU2728674C2 |
METHOD OF PREDICTING EFFICIENCY OF IMMUNOTHERAPY BASING ON ESTIMATION OF LEVEL OF EXPRESSION OF CYTOKINE MRNK IN KIDNEY CANCER TISSUE | 2009 |
|
RU2517082C2 |
METHOD FOR PREDICTION OF DEVELOPING ACUTE RENAL FAILURE BY LEVEL OF EXPRESSION OF GENES CASP3, CASP8 AND CASP9 AFTER SHORT-TERM KIDNEY ISCHEMIA | 2015 |
|
RU2599099C1 |
METHOD FOR PREDICTING EFFECTIVENESS OF TREATMENT OF RHEUMATOID ARTHRITIS WITH DRUG OLOKIZUMAB USING EPIGENETIC MARKERS | 2020 |
|
RU2749248C1 |
DIAGNOSTIC METHOD OF RENAL CELL CARCINONMA | 2016 |
|
RU2643586C1 |
METHOD FOR DETECTING TRANSCRIPTION LEVEL OF GENE CODING HUMAN CHEMOKINE CCL2 (MCP-1) AND KIT FOR IMPLEMENTING IT | 2012 |
|
RU2522801C2 |
Authors
Dates
2021-05-13—Published
2018-10-24—Filed